Liver Disease of Pregnancy: Cholestasis & Acute Fatty Liver
One itches, one fails: sorting the liver diseases unique to late pregnancy
Intrahepatic cholestasis of pregnancy
Presentation. Intense pruritus, worst on the palms and soles and at night, begins in the late second or third trimester. The skin shows only excoriations, with no primary rash, and jaundice is uncommon. Sex-steroid metabolites overload canalicular bile transport in genetically susceptible women (ABCB4 and ABCB11 variants), so the disorder clusters in families and is more common with twins.
Diagnosis. Pruritus plus serum total bile acids ≥10 µmol/L confirms it; transaminases rise mildly to moderately and bilirubin little. Atypical labs prompt a search for viral hepatitis, gallstones or preeclampsia, and a prolonged PT from fat malabsorption is corrected with vitamin K.
Treatment. Ursodeoxycholic acid (10 to 21 mg/kg/day, commonly 10 to 15) relieves itching and lowers bile acids and transaminases but has not been shown to prevent stillbirth. Antihistamines only aid sleep, and antenatal testing does not reliably predict the sudden fetal deaths.
Delivery timing. Stillbirth, preterm birth, meconium-stained fluid and neonatal respiratory distress climb with the bile acid level. Bile acids ≥100 µmol/L call for delivery at 36 weeks; lower levels allow delivery between 36 and 39 weeks, depending on the level.
After delivery. Itching fades within days and labs normalize within weeks; persistent abnormalities suggest underlying liver disease such as primary biliary cholangitis or hepatitis C. Cholestasis commonly recurs in later pregnancies and can be provoked by estrogen-containing contraceptives.
Acute fatty liver of pregnancy
Mechanism. Failed mitochondrial fatty acid oxidation causes microvesicular fatty infiltration of hepatocytes. A fetus with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, an autosomal recessive defect, returns toxic long-chain metabolites to its heterozygous mother. Twins, a male fetus and low maternal BMI also raise risk; overall, AFLP complicates about 1 in 7,000–20,000 deliveries.
Presentation. Usually after 30 weeks or just postpartum: malaise, anorexia, nausea, vomiting and epigastric pain, then jaundice and encephalopathy. Polyuria and polydipsia from transient diabetes insipidus (the failing liver clears placental vasopressinase poorly) may come first, and about half of patients have hypertension.
Laboratory signature. Synthetic failure dominates: hypoglycemia, prolonged INR, low fibrinogen and antithrombin, high ammonia and bilirubin, acute kidney injury (rising creatinine and uric acid) and leukocytosis, with only moderately raised transaminases. The diagnosis is clinical, supported by ≥6 of the 14 Swansea criteria without another cause; biopsy showing microvesicular fat is rarely needed and risky with coagulopathy.
- Stabilize in intensive careIV dextrose, FFP and cryoprecipitate for coagulopathy, blood pressure control
- Deliver promptlyAt any gestational age; induction if progress will be quick, cesarean for usual indications after correcting coagulopathy
- Support recoveryAnticipate postpartum hemorrhage; most women recover over weeks, and transplant is rarely needed
- Test the newbornScreen for a fatty acid oxidation disorder and offer the parents genetic counseling
An infant with LCHAD deficiency risks hypoketotic hypoglycemia, cardiomyopathy and sudden death; if both parents are carriers, each pregnancy has a 25% chance of an affected fetus.
Distinguishing the mimics
Timing first. Hyperemesis gravidarum causes a mild first-trimester transaminase rise that resolves with rehydration; cholestasis appears in the late second or third trimester; preeclampsia, HELLP and AFLP belong to the third trimester and can present after delivery; viral hepatitis and gallstones occur at any time.
| Feature | Intrahepatic cholestasis | Acute fatty liver | HELLP syndrome |
|---|---|---|---|
| Timing | Late 2nd–3rd trimester | 3rd trimester or postpartum | 3rd trimester or postpartum |
| Hallmark | Pruritus of palms and soles, no rash | Vomiting, abdominal pain, jaundice, encephalopathy | Hypertension, RUQ or epigastric pain |
| Key labs | Bile acids ≥10 µmol/L; mild transaminase rise | Hypoglycemia, ↑INR, ↓fibrinogen, ↑ammonia, AKI | Hemolysis, ↑LDH, platelets <100,000/μL; normal glucose |
| Maternal danger | Low | Liver failure, hemorrhage | Hemorrhage, eclampsia, hepatic rupture |
| Management | Ursodiol; deliver at 36–39 weeks by bile acid level | Stabilize and deliver at any gestation | Magnesium, BP control, delivery |
HELLP versus AFLP. HELLP brings hemolysis (schistocytes, raised LDH), platelets <100,000/μL and hypertension with normal glucose and usually normal INR and fibrinogen; hypoglycemia, low fibrinogen and high ammonia point to AFLP. The two can overlap, and both are cured by delivery.
Viral hepatitis. Transaminases often exceed 1,000 with positive serology. Hepatitis E, spread fecal-orally in South Asia and Africa, can become fulminant in the third trimester with high maternal mortality. Herpes simplex hepatitis causes fever and very high transaminases, often without skin lesions or much jaundice, and needs empiric IV acyclovir.
Gallstones. Estrogen raises biliary cholesterol and progesterone slows gallbladder emptying, so biliary colic and cholecystitis are common in pregnancy; RUQ pain after meals, fever and a Murphy sign lead to ultrasound, while bile acids and glucose stay normal.